Suppr超能文献

慢性肝病患者肝脏中细胞色素P450 3A4亚型及其基因表达的不同改变。

Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.

作者信息

Yang Li-Qun, Li Shen-Jing, Cao Yun-Fei, Man Xiao-Bo, Yu Wei-Feng, Wang Hong-Yang, Wu Meng-Chao

机构信息

Department of Anesthesiology, Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University, Shanghai 200438, China.

出版信息

World J Gastroenterol. 2003 Feb;9(2):359-63. doi: 10.3748/wjg.v9.i2.359.

Abstract

AIM

To determine whether parenchymal cells or hepatic cytochrome P450 protein was changed in chronic liver diseases, and to compare the difference of CYP3A4 enzyme and its gene expression between patients with hepatic cirrhosis and obstructive jaundice, and to investigate the pharmacologic significance behind this difference.

METHODS

Liver samples were obtained from patients undergoing hepatic surgery with hepatic cirrhosis (n=6) and obstructive jaundice (n=6) and hepatic angeioma (controls, n=6). CYP3A4 activity and protein were determined by Nash and western blotting using specific polychonal antibody, respectively. Total hepatic RNA was extracted and CYP3A4cDNA probe was prepared according the method of random primer marking, and difference of cyp3a4 expression was compared among those patients by Northern blotting.

RESULTS

Compared to control group, the CYP3A4 activity and protein in liver tissue among patients with cirrhosis were evidently reduced. (P<0.01) Northern blot showed the same change in its mRNA levels. In contrast, the isoenzyme and its gene expression were not changed among patients with obstructive jaundice.

CONCLUSION

Hepatic levels of P450s and its CYP3A4 isoform activity were selectively changed in different chronic liver diseases. CYP3A4 isoenzyme and its activity declined among patients with hepatic cirrhosis as expression of cyp3a4 gene was significantly reduced. Liver's ability to eliminate many clinical therapeutic drug substrates would decline consequently. These findings may have practical implications for the use of drugs in patients with cirrhosis and emphasize the need to understand the metabolic fate of therapeutic compounds. Elucidation of the reasons for these different changes in hepatic CYP3A4 may provide insight into more fundamental aspects and mechanisms of imparied liver function.

摘要

目的

确定慢性肝病中实质细胞或肝细胞色素P450蛋白是否发生变化,比较肝硬化患者与梗阻性黄疸患者之间CYP3A4酶及其基因表达的差异,并探讨这种差异背后的药理学意义。

方法

从接受肝脏手术的肝硬化患者(n = 6)、梗阻性黄疸患者(n = 6)和肝血管瘤患者(对照组,n = 6)获取肝脏样本。分别采用Nash法和使用特异性多克隆抗体的western印迹法测定CYP3A4活性和蛋白。提取肝脏总RNA,按照随机引物标记法制备CYP3A4 cDNA探针,通过Northern印迹法比较这些患者中cyp3a4表达的差异。

结果

与对照组相比,肝硬化患者肝组织中的CYP3A4活性和蛋白明显降低(P<0.01)。Northern印迹显示其mRNA水平有相同变化。相比之下,梗阻性黄疸患者中同工酶及其基因表达未发生变化。

结论

在不同的慢性肝病中,肝脏P450s水平及其CYP3A4同工型活性发生了选择性改变。肝硬化患者中CYP3A4同工酶及其活性下降,因为cyp3a4基因的表达显著降低。肝脏消除许多临床治疗药物底物的能力将因此下降。这些发现可能对肝硬化患者的用药具有实际意义,并强调需要了解治疗性化合物的代谢命运。阐明肝脏CYP3A4这些不同变化的原因可能有助于深入了解肝功能受损的更基本方面和机制。

相似文献

引用本文的文献

3
Polymorphism of is associated with anti-tuberculosis drug-induced hepatotoxicity.是与抗结核药物性肝损伤相关的多态性。
Pharmacogenomics. 2024;25(5-6):241-247. doi: 10.1080/14622416.2024.2346069. Epub 2024 May 10.
6
Brigatinib pharmacokinetics in patients with chronic hepatic impairment.布加替尼在慢性肝损伤患者中的药代动力学。
Invest New Drugs. 2023 Jun;41(3):402-410. doi: 10.1007/s10637-023-01339-6. Epub 2023 Apr 13.

本文引用的文献

3
Polymorphism of metabolic genes and susceptibility to occupational chronic manganism.
Biomarkers. 2002 Jul-Aug;7(4):337-46. doi: 10.1080/13547500210146740.
6
Microsomal cytochrome P450 and eicosanoid metabolism.微粒体细胞色素P450与类花生酸代谢。
Cell Mol Life Sci. 2002 May;59(5):780-9. doi: 10.1007/s00018-002-8466-y.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验